SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Anti-Envelope glycoprotein H and L [rec-RC-IgG] Bulk Size Ab04131-23.0-BT

Isotype and Format: Rabbit IgG, Kappa
Clone Number: rec-RC-IgG
Alternative Name(s) of Target: gHgL; gH; gL; envelope glycoprotein H; envelope glycoprotein L; Varicella zoster virus; VZV; human herpesvirus 3; HHV-3; HHV3; Human alpha herpesvirus 3; Chickenpox; IgG-RC
UniProt Accession Number of Target Protein: Q775J3; Q9J3N1
Published Application(s): IP, neutralize, IHC
Published Species Reactivity: Varicella zoster virus (VZV)
Immunogen: The original antibody was isolated from circulating blood plasmablast of a 59-year-old VZV-seropositive man recently immunized with zoster vaccine Zostavax.
Specificity: This antibody targets the domain IV region of envelope glycoprotein B of the Varicella zoster virus (VZV) also known as the human herpesvirus 3 (HHV-3, HHV3) or Human alpha herpesvirus 3. This DNA virus from the herpes virus group can infect humans causing chickenpox in children and shingles (herpes zoster) in adults. Varicella is characterized by a maculopapular, vesicular rash that can be pruritic and evolves into dried crusts (scabs) over a 3- to 7-day period. Chicken pox is considered contagious beginning 1-2 days before rash onset until all lesions have crusted (scabbed).
Application Notes: This antibody was used for the immunohistochemical staining of fixed and unfixed VZV-infected and control human lung fibroblast cells. This antibody was also reported to neutralize VZV infection in a plaque reduction assay. The concentration of IgG that produced 50% plaque reduction was 0.6 µg/ml. This antibody was also used for the immunoprecipitation of VZV-infected cells (PMID: 23077312).
Antibody First Published in: Birlea et al. Human Anti-Varicella-Zoster Virus (VZV) Recombinant Monoclonal Antibody Produced after Zostavax Immunization Recognizes the gH/gL Complex and Neutralizes VZV Infection. J Virol. 2013 Jan; 87(1): 415–421. PMID:23077312
Note on publication: This paper describes the generation of a recombinant monoclonal antibody from the circulating blood plasmablast of a VZV-seropositive man immunized with zoster vaccine Zostavax.

Product Form

Size: 1 mg Purified antibody in bulk size.
Purification: Protein A affinity purified
Supplied In:

PBS only.

Storage Recommendation: Store at 4ºC for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20ºC.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.